VANCOUVER, Aug. 3 /CNW/ - Med BioGene Inc. (TSX Venture: MBI) is pleased to announce the results of its pre-clinical studies involving its Diagnostic Lymphoma Bioarray. The studies of fifty RNA samples derived from human lymphoma tissues suggest that MBI's Diagnostic Lymphoma Bioarray successfully differentiated between genes in both the diseased and healthy control samples. Moreover, the results revealed a high dissimilarity between six lymphoma subtypes (Diffuse Large B-Cell, Mantle Cell, Follicular, Hodgkin, Marginal Zone and Small Lymphocytic) and the healthy control samples, indicating that the bioarray is able to detect differential expression profiles. The samples used in the studies did not include the subtype T-Cell Lymphoma; however, prior studies suggest that the bioarray is able to distinguish this subtype from healthy control samples. Sample replicates were also highly similar to one another, indicating a consistency in the bioarray. "We are very pleased with these results and are enthusiastic about the prospects of our Diagnostic Lymphoma Bioarray as an effective tool for the accurate and rapid detection of lymphoma subtypes. We have been able to narrow our lymphoma biomarkers to approximately 100 genes, thus increasing the effectiveness of the product as a manageable diagnostic tool. Further studies, however, may result in the finding of additional biomarkers that will be included in our bioarray. These studies were performed on GE Healthcare's CodeLink System using custom bioarrays made exclusively for, and containing genetic content developed by, Med BioGene. We are also in the process of confirming our results on a second platform utilizing Applied BioSystem's 7500 Real-Time PCR System", noted Dr. T. Nathan Yoganathan, Chief Scientific Officer of MBI. "In addition to the use of our bioarray as a diagnostic tool, there is an increasing consensus in the medical community that effective biomarkers are needed to unlock innovation in therapeutic development and treatment. With a robust set of qualified lymphoma biomarkers, the safety of new therapeutics could be increased, products could get to patients in less time and treatment decisions could be more informed. Med BioGene is truly at the forefront of personalized medicine", stated Erinn Broshko, Chief Executive Officer of MBI. About Med BioGene MBI is a biotechnology company with advanced research expertise in gene expression technology. MBI is at the forefront of personalized medicine and it's mission is to become the market leader in the supply of content for molecular-based diagnostic micro arrays. MBI intends to fulfill this mission by developing and marketing genetic content for molecular-based human diagnostic tests. Molecular diagnostics, based on genetic expression, is a developing technology field that has the potential to replace certain of today's standard diagnostic tests. MBI intends to utilize its expertise in gene expression, bioinformatics and micro arrays to develop the diagnostic tests' genetic content. From the tens of thousands of genes in the human genome, MBI is identifying those genes, known as "biomarkers," which mark the presence of various disease conditions. MBI is initially developing diagnostic tests for certain types of cancer, specifically lymphoma and leukemia. In the future, MBI intends to develop diagnostic tests to identify the earliest stages of heart disease or the presence of an infectious disease. These diagnostic test kits will be designed to provide additional information to physicians to allow them to create more suitable and more effective treatments for an improved patient prognosis. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release. Certain statements in this press release contain forward-looking information under applicable Canadian securities legislation. Words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "will," "would" and similar expressions are intended to identify forward-looking information, although not all forward-looking information contains these identifying words. Forward looking information includes, but are not limited to, those with respect to future profits, future product revenues, future operations and plans, the use of proceeds from financings, the timing of clinical trials and the completion date for clinical trials and the prospects for negotiating partnerships or collaborations and their timing. These forward-looking statements or information are only predictions based upon MBI's current expectations, and actual events or results may differ materially. MBI may not actually achieve the plans, intentions or expectations disclosed in its forward-looking information. Forward-looking information is subject to known and unknown risks and uncertainties and are based on uncertain assumptions that could cause MBI's actual results and the timing of events to differ materially from those anticipated in such forward-looking information. You are cautioned not to place undue reliance on this forward-looking information, which speaks only as of the date of this press release. Our forward-looking information does not reflect the potential impact of any future partnerships, collaborations, acquisitions, mergers, dispositions, joint ventures or investments MBI may make. All forward-looking information is qualified in its entirety by this cautionary statement and MBI undertakes no obligation to revise or update any forward-looking information as a result of new information, future events or otherwise after the date of this press release, other than as required by applicable law. %SEDAR: 00023675E